The differentiation of pluripotent and multipotent stem cells into insulin-producing cells has the potential to create a renewable supply of replacement b cells with tremendous utility in the treatment of diabetes. The purpose of this review is to summarize recent advancements in the field, with emphasis on the limitations of this technology as it relates to the b cell.
Introduction
Diabetes mellitus results from either a complete or a relative deficiency of insulin, a protein whose production is restricted almost entirely to the pancreatic b cells [1] . Worldwide, diabetes is estimated to affect 246 million individuals, and the prevalence of this disease is increasing to epidemic proportions [2] [3] [4] . Currently, pancreatic and islet transplantation are the only treatments that offer patients the possibility of a cure. Both methods of transplantation, however, are limited by organ availability. Moreover, enthusiasm for islet transplantation has been tempered by disappointing results of long-term outcome studies, which suggest that only 10-15% of patients demonstrate continued insulin independence 5 years after transplantation [5] . Thus, recent research efforts have focused on exploiting the principles that guide b-cell development with the hope of creating a renewable and limitless source of insulin-producing cells from primitive biologic precursors [6 -8 ,9 ,10] . In the current review, we will summarize the state of this field, with emphasis on the development of insulin-producing cells from human embryonic stem cells (hESCs). An accompanying review describes the status of current research efforts focused on the production of functional b cells from resident pancreatic precursor cells.
An overview of b-cell development
The adult pancreas has dual exocrine and endocrine functions. The exocrine tissue comprises about 80% of the pancreas and consists of acinar and ductal cells [11 ] . The endocrine pancreas is composed of clusters of hormone-producing cells known as the islets of Langerhans. Islets are made up of a, b, g, e, and F cells, which synthesize and secrete glucagon, insulin, somatostatin, ghrelin, and pancreatic polypeptide, respectively [12] . A common progenitor cell is responsible for the formation of acinar, ductal, and islet tissue. A variety of gene deletion studies has been performed to define the pathways of differentiation for each cell type. These studies have provided a framework for pancreas formation, which is characterized by a spatial and temporal signaling cascade that includes both cell-intrinsic (e.g. transcription factors) and nonintrinsic (e.g. intercellular signaling) mechanisms. The subject of pancreatic organogenesis has been extensively reviewed elsewhere [13 ,14 ] . Because the fundamentals of embryogenesis form the basis of strategies to convert primitive precursors to b cells, we will consider briefly the embryonic pathway from a common progenitor to a functional insulinproducing b cell.
The pancreas develops from definitive endoderm, which forms the primitive gut tube. Initiation of the pancreatic programme requires extrinsic signals that lead to inhibition of hedgehog signaling and increased retinoid signaling [15, 16] within the discrete region destined to become pancreas. Subsequently, a series of cell-intrinsic signals from transcription factors direct the gene expression programme that guides the developmental tree. The master transcription factors that sit atop this developmental tree are the homeobox transcription factor, Pdx-1, and the basic helix-loop-helix protein, Ptf1a, which together mark cells of endodermal origin destined to form the mature pancreas [17] [18] [19] [20] . The transcription factor responsible for driving Pdx-1/Ptf1a-positive progenitor cells to an endocrine rather than an exocrine fate is the basic helix-loop-helix protein Neurog3. Notch signaling appears to be instrumental in maintaining a balance between endocrine and exocrine pathways via a 'lateral inhibition' pathway of intercellular communication. Cells expressing Neurog3 signal through Notch ligands to neighboring cells, which subsequently express Hes-1, a potent suppressor of Neurog3 expression [21] . Thus, this pathway allows for the spatial separation between endocrine and exocrine components of the pancreas as seen in the mature organ. A subset of Neurog3-positive cells that are destined to become b cells then initiates a cascade of transcription factors that share responsibility in guiding cells towards this predetermined lineage. This list includes Insm1, NeuroD1/ Beta2, Pax4, Nkx2.2, Nkx6.1, Hlxb9, and MafA, and again Pdx-1, which plays an additional role to maintain mature b-cell function. Table 1 ( ) summarizes our current understanding of the transcriptional regulators of pancreatic development.
Human embryonic stem cells as precursors
There are at least two major types of stem cells: tissue or organ-specific stem cells and embryonic stem cells. Tissue-specific stem cells are also referred to as adult stem cells. These cells are capable of self-renewal and are Development of insulin-producing cells from primitive biologic precursors Evans-Molina et al. 57 Ptf1a [28] Expressed in all pancreatic progenitors; regulates differentiation of exocrine cells Hypoplastic pancreas and loss of exocrine cells Sox9 [29] Promotes proliferation and maintenance of pancreatic progenitor cells Pancreatic hypoplasia and reduction of pancreatic progenitors Sox4 [30] Expressed in pancreatic buds during early development
Reduced number of endocrine cells
Pbx1 [31, 32] Forms a complex with Pdx-1 that is necessary for pancreatic progenitor pool expansion Pancreatic hypoplasia and defects in endocrine and exocrine cell differentiation Tcf2 [33, 34] Controls expression of Hnf6 Pancreatic agenesis Endocrine precursors Neurog3 [35] Expression required for the specification all four endocrine cell types
Complete absence of endocrine cells
Isl1 [36] Required for the development of dorsal pancreatic mesenchyme
Absence of islet cells
NeuroD1 [37] Expressed in endocrine progenitors Marked reduction in b cells and altered islet architecture Insm1 [38] Necessary for endocrine precursor differentiation Endocrine precursors form but lack hormone expression Pax6 [39] Required for endocrine cell differentiation Altered islet morphology and decrease in all endocrine cell types b-cell specification Pax4 [40] Regulates development of endocrine cells Reduced numbers of b and d cells MafB [41] Expressed in immature a and b cells during development
Reduced a and b cells
MafA [42, 43] Switch from MafB to MafA observed in differentiation of b cells; required for insulin gene transcription
No defects in development but impaired insulin secretion
Nkx2.2 [44, 45] Has dual roles as a transcriptional activator and repressor during development Reduced a, b, and pancreatic polypeptide cells but increased numbers of e cells. Nkx6.1 [46] Plays a role in b-cell formation and maturation postnatally
Reduced numbers of mature b cells considered to multipotent, which means that they possess the ability to produce a limited number of cell types. This situation is in contrast to embryonic stem cells, which are derived from the inner cell mass of the developing blastocyst. Embryonic stem cells are pluripotent, or capable of forming virtually any cell type [47 ] . Given these unique characteristics, there is obvious enthusiasm for the use of embryonic stem cells to generate a limitless supply of insulin-producing cells.
The first successful strategies to develop b cells from embryonic stem cells utilized embryoid body formation as the initial step [48, 49] . When embryonic stem cells are cultured in the absence of leukemia-inhibitory factor or mouse-embryonic fibroblasts, they differentiate spontaneously into three-dimensional aggregates known as embryoid bodies. Embryoid body formation is followed by the differentiation of all three germ cell layers, a process known as gastrulation [50 ] . In the early years of experimentation, a relatively low percentage of insulin-positive cells were recovered using this approach. As a result, a variety of enhancement and selection techniques was developed [51] [52] [53] . These methods were often combined with the ectopic overexpression of transcription factors that are known to drive b-cell formation during development (see Table 1 ) [54] . Subsequent careful analysis refuted the results of a many of these early differentiation protocols and suggested that insulinpositive staining in these cultures may have actually resulted from insulin uptake from the culture medium. Thus, current standards for analysis of cultures differentiated in vitro include measurement of C-peptide, insulin gene expression, electron microscopy for identification of insulin granules, and ultimately demonstration that such cells reverse hyperglycemia for sustained periods in animal models of diabetes [55] .
As the field has developed, more sophisticated methods have been used to generate insulin-producing b cells. Whereas some protocols still utilize embryoid body formation, others have adopted approaches to avoid this initial step. In these protocols, embryonic stem cells have been first driven to form definitive endoderm. This strategy purportedly offers the advantage that it increases the yield of insulin-positive cells, as the maintenance of a two-dimensional culture system would allow for the uniform exposure of all cells to differentiation factors [8 ,9 ] . However, those groups that continue to favor the initial formation of embryoid bodies argue that the three-dimensional structure of embryoid bodies promotes the necessary intercellular interactions that more closely recapitulate embryonic development [56 ] .
Under normal conditions, definitive endoderm forms in the presence of high levels of transforming growth factor-beta (TGFb)/nodal signaling [57] . Activin, a TGFb signaling ligand, has been used in combination with a variety of factors including Wnt3a, sodium butyrate, bone morphogenetic protein 4 (Bmp4), and retinoic acid, to induce the formation of definitive endoderm [8 ,9 ,56 ] . In addition to the activation of nodal signaling, the specification of definitive endoderm also appears to require the release of inhibitory signaling from insulin and insulin-like growth factor I (IGF-I) via the phosphatidylinositol 3-kinase (PI3K) pathway. Thus, specification of definitive endoderm has been accomplished through the use of serum-free conditions or chemical inhibitors of PI3K, such as LY294002 and AKTI-II [58 ] . Expression of SOX17, CER, FOXA2, chemokine (C-X-C motif) receptor 4 (CXCR4), and Hierarchical nonlinear factor analysis (HNFa) have been used as markers to confirm the presence of endodermal tissue [6 ,9 ,59,60] .
Several groups have published recent accounts of hESC differentiation into insulin-producing cells by utilizing many of the above advancements. The protocols developed by Phillips et al. [56 ] and Jiang et al. [8 ] consider four main steps in the conversion of hESCs to b cells: formation of definitive endoderm, formation of pancreatic endoderm, formation of endocrine tissue, and b-cell maturation (Fig. 1a ). Phillips et al. [56 ] allowed embryoid bodies to form and subsequently treated with activin and Bmp4 to enhance formation of definitive endoderm. Fibroblast growth factor 18 (FGF18) was used alone in
Step 2, and this was followed by treatment with a number of additional growth factors in Step 3 for endocrine induction, which included epidermal growth factor (EGF), TGFa, IGF-I, IGF-II, and vascular endothelial growth factor (VEGF). In the final maturation step, cells were exposed to hepatocyte growth factor (HGF), pancreatic polypeptide, and forskolin. In this optimized protocol, about 85% of progenitors expressed Pdx-1 at day 12, and 65% of cells developed into endocrine cell types. Approximately 30% of embryoid bodies expressed insulin by in-situ hybridization at day 34. Consistent with an immature endocrine cell type, glucagon and somatostatin were present as well. These cells had a modest C-peptide response to glucose challenge (about 1.5 times baseline). Following transplantation into streptozotocin (STZ)-treated severe combined immunodeficiency (SCID) mice, they retained the ability to express Pdx-1 and insulin but lacked the ability to consistently lower blood glucose in diabetic mice [56 ] .
Jiang et al. [8 ] developed a 36-day protocol involving the use of feeder cell-free suspension cultures, which avoided the spontaneous formation of embryoid bodies (Fig. 1b) . Definitive endoderm was specified by treatment with activin and sodium butyrate, a histone deacetylase inhibitor. In the second step, noggin, basic fibroblast growth factor (bFGF), and EGF were used to form pancreatic endoderm. Noggin is a protein known to inhibit TGFb signaling. Following withdrawal of bFGF to avoid hepatic differentiation, cells were treated with nicotinamide and IGF-II for continued maturation to a b-cell lineage.
Resulting cells expressed insulin, glucagon, and somatostatin, similar to results seen by Phillips et al. [56 ] . The islet-like clusters were shown to have morphology similar to b cells using electron microscopy, and these cells were able to release C-peptide in response to glucose exposure for prolonged periods [8 ] .
D'Amour et al. [9 ] published a detailed differentiation protocol in 2006. The protocol differed in those described previously in that several additional steps of development were considered ( Fig. 2a ). They also avoided the formation of embryoid bodies but used mouse fibroblast feeder layers. In Stage 1, definitive endoderm was specified by activin and Wnt3a. This procedure was followed by treatment with FGF10 and the hedgehog signaling inhibitor, KAAD-cyclopamine, to induce formation of the primitive gut tube. Posterior foregut was specified by the addition of retinoic acid. Stage 4 involved the differentiation of pancreatic endoderm with exendin 4 and g-secretase inhibitor (DAPT), which was used to inhibit Notch signalling. Exendin 4 acts as an agonist of glucagon-like peptide-1 (GLP-1) and has been shown to have proliferative and anti-apoptotic effects on islet tissue [61, 62] . In the final stage, an endocrine phenotype was specified by the addition of IGF-I and HGF. Resulting cells were found to express insulin, glucagon, somatostatin, pancreatic polypeptide, and ghrelin. These cells released C-peptide in response to glucose. The same group published a follow-up paper in 2008, in which their protocol was modified slightly (Fig. 2b) . At day 12 in this new protocol, at a point when the cells exhibited a phenotype of committed pancreatic endoderm, they were transplanted into SCID mice. After 3 months, the grafts displayed architecture consistent with a mature islet, and costaining of islet hormones was not noted within the same cells. During glucose tolerance testing, insulin was secreted in a regulated, predictable manner. STZ was then used to preferentially ablate the native b cells of recipient mice; hyperglycemia was successfully prevented by the grafts in these animals [6 ,9 ,57] .
In a similar experiment, Shim et al. [7 ] cultured embryoid bodies in the presence of serum for 4 days, followed by serum withdrawal and the addition of activin and retinoic acid. The resulting cells were cultured for several more days and then transplanted into STZ-treated mice. Within 4 days of transplantation, blood glucose in the recipient mice improved and they remained normoglycemic until the grafts were removed. The grafts contained structures that resembled islets but many cells stained positive for insulin and glucagon, indicating an immature phenotype.
Multipotent stem cells as precursors
Given the ethical, political, and safety concerns surrounding research with hESCs, the identification and differentiation of adult tissue-specific stem cells into insulinproducing tissue offers an attractive alternative. Jin et al.
[63 ] recently published a protocol using immortal liver epithelial progenitor cells (LEPCs), which is a stem-like cell line derived from regenerative liver. Pdx-1 was stably expressed in LEPCs, under high-glucose/low-serum conditions, followed by treatment with a variety of growth factors. The resulting cells stained positive for insulin and C-peptide and robustly secreted insulin in response to high glucose. Further, diabetes was ameliorated after transplantation into STZ-treated SCID mice.
Similarly, Hori et al. [64] used neural progenitor cells and subjected them to a differentiation protocol consisting of glucose deprivation and retinoic acid. The resulting cells expressed low levels of insulin and secreted insulin in response to a glucose challenge. Following transplantation into immunocompromised mice, the engrafted cells responded to glucose challenge, but absolute insulin release remained quite low.
Given the ease of isolation and ready availability, bone marrow-derived stem cells represent a particularly attractive source of progenitors for differentiation protocols. To date, there has been ample controversy in this field. Many believe there is no definite evidence to support the idea that bone marrow-derived cells and progenitors have the ability to differentiate into insulin-producing cells. They do, however, acknowledge that cells of this type may play a role in supporting b-cell regeneration and in abrogating immune injury in type 1 diabetes mellitus [65 ] . Notwithstanding this debate, several interesting in-vitro observations have been made recently. Moriscot, et al. [66] isolated multipotent stem cells from human bone marrow aspirates. Following overexpression of Pdx-1, homeo box HB9 (HLXB9), and FOXA2 using an adenovirus system, insulin expression could be detected. Ai et al. [67 ] published a recent account in which mesodermal progenitor cells (MPCs) were isolated from human fetal bone marrow aspirates. A previous study [68] suggested that MPCs might have pluripotent properties. These cells were labeled with green fluorescent protein and engrafted with human fetal pancreatic tissue into SCID mice for in-vivo maturation. The resulting islet-like clusters were glucose responsive and able to reverse hyperglycemia in non-obese diabetic (NOD)-SCID mice. Importantly, the islet clusters remained green fluorescent protein (GFP) positive pointing to the differentiation of MPCs rather than a pancreatic stem cell.
Limitations of current technologies
Despite the success of the protocols described in this review, there is significant work to be done before these ideas can be applied clinically. Paramount to consider are the safety implications of transplanting grafts that may be contaminated with undifferentiated pluripotent cells, as the potential for teratoma formation exists. At the completion of their study, Kroon et al. [6 ] removed transplanted grafts from recipient SCID mice. Pathological examination of grafts revealed a teratoma in one out of 46 grafts and teratomatous tissue in six others. Additionally, karyotypic instability has been described in longterm cultured hESCs, and future studies should be designed to address these issues [69] .
Notwithstanding these safety concerns, there are additional technical considerations. Most importantly, none of the protocols described have recapitulated precisely the exquisite machinery that enables the normal b cell to sense glucose and release insulin in a truly normal manner. In this regard, in-vivo maturation of partially differentiated cells by factors yet to be defined has offered the best results, but only highlights the fact that there is still much to learn about pancreatic development and islet biology. Although not specifically discussed here, transplantation of any cell type brings with it concerns regarding immune tolerance, and there are numerous studies under way to investigate strategies aimed at inducing tolerance prior to stem cell transplantation [70] . In addition to these concerns, there are issues of scale as even the most successful protocols produce relatively low numbers of insulin-positive cells. One could envision revisiting the idea of forced overexpression of selected transcriptional regulators like Pdx-1 or Neurog3 at certain steps to increase the fidelity of this process. Dominguez-Bendala et al. [71] published a report describing fusion of Neurog3 to the HIV/trans-activating (TAT) protein transduction domain. This is a technology that ensures efficient uptake of a protein into a cell of interest, allows for transient overexpression, and could have utility in differentiation protocols as a means to increase the yield of insulin-positive cells. Finally, no discussion of the future of stem cell therapy would be complete without the acknowledgement that political and ethical considerations may influence the pace of future discovery in this field [72 ] . One possible method that has the potential to circumvent these social limitations involves the transformation of somatic cells into induced pluripotent stem cells (iPS). A recent report from Tateishi et al. [73] describes a protocol in which human skin fibroblasts were transformed into iPS cells and subsequently differentiated into insulin-producing cells. Protocols of this kind might also offer immune advantages, as a patient's own skin fibroblasts could be used in differentiation strategies.
Conclusion
Even in the context of the limitations outlined above, it is important to acknowledge that there has been incredible progress in the field of stem cell research within the last several years. Although it should be emphasized that none of the protocols discussed here have been successful in reproducing a fully functional mature b cell, the generation of insulin-producing cells that demonstrate glucose responsivity is impressive and encouraging. Although significant research is still required, a future in which diabetes is treated with b-cell replacement seems an attainable goal.
